About us

Quirem Medical BV

Quirem Medical is an emerging medical device company with a mission to develop the next generation microspheres for targeted interventional treatment of liver malignancies.

Quirem Medical BV is a spin-off company of the University Medical Center Utrecht (UMCU) and commercializes, manufactures and distributes a new type of radioembolization microspheres based on the isotope holmium, named QuiremSpheres®. QuiremSpheres® has received CE mark approval in April 2015 and is currently available in select markets in Europe. Radioembolization is an efficacious treatment modality for advanced unresectable liver tumors. We believe that the unique imaging capabilities of holmium microspheres can further drive treatment outcome by tailoring the treatment to the patient.

Quirem Medical’s ambition is to provide a real-time, image guided, personalized radioembolization treatment with improved patient outcome and lower the hurdles for adoption of radioembolization for the treatment of cancer.

Quirem Medical Management team

Jan Sigger

Chief Executive Officer

Jan Sigger held senior management positions at Royal Dutch Shell and Akzo Nobel before joining Nucletron, the global market leader in brachytherapy as CFO in 2008. Between 2008 – 2012 he was instrumental in transforming Nucletron into the fastest growing radiotherapy company and managed the sale from private equity ownership to Elekta AB in 2011. Jan Sigger is a Master in Business Economics and holds a post-graduate degree as Chartered Accountant.

Frank Nijsen

Chief Scientific Officer

Frank Nijsen has performed research into Holmium microspheres for more than 20 years. He has led the successful valorisation of the Holmium technology and was instrumental in the creation of the spin-off company Quirem Medical. He holds as inventor many patents in the field. Frank Nijsen holds a doctorate in Medical Biology and is a Associate Professor at the University Medical Center Utrecht.

Partners

University Medical Center Utrecht

By building on its long term partnership with the University Medical Center Utrecht and supported by a strong patent base, both parties are committed to collaborate in the further development of the Holmium technology base to bring better cancer treatment solutions to patients worldwide.

University Medical Center Utrecht strives to achieve the highest levels in, patient care, scientific research and education. By dedicating ourselves to continuous improvements, we can pioneer cutting-edge treatments, foster groundbreaking findings, and deliver a standard of care that meets the healthcare needs for today, and the future.

Terumo Corporation

On January 29th 2016 Terumo Corporation and Quirem Medical expanded their Strategic Alliance. Terumo thereby became the exclusive global distributor for the radioembolization solutions developed by Quirem Medical.

Tokyo-based Terumo Corporation is one of the world’s leading medical device manufacturers with over $4 billion in sales and operations in more than 160 nations. Founded in 1921, the company develops, manufactures, and distributes world-class medical devices including products for use in interventional procedures, cardiovascular surgery, and transfusion medicine; the company also manufactures a broad array of syringe and hypodermic needle products for hospital and physician office use and also supplies drug delivery/injection devices to pharmaceutical firms. Terumo Corporation’s shares are listed on the first section of the Tokyo Stock Exchange and are a component of the Nikkei, Japan’s leading stock index.